Agree. Thank you NYD for poiting out the following from the CC:
"Company that are moving along rather nicely such as the restart of the Alergen line & the start-up of the Remote Patient Monitoring. Both appear to be moving along very nicely and they both appear to be very close to Revenue producing which is pretty significant. Obviously, this Company has a lot more going for it than just the "Complete Vaccine" & NGIO Up-Listing".
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.